Goldman Sachs’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$231M Sell
250,800
-336,500
-57% -$341M 0.03% 617
2025
Q4
$631M Sell
587,300
-242,300
-29% -$232M 0.08% 235
2025
Q3
$633M Buy
829,600
+615,700
+288% +$458M 0.08% 235
2025
Q2
$167M Sell
213,900
-259,600
-55% -$202M 0.02% 632
2025
Q1
$391M Buy
473,500
+269,600
+132% +$224M 0.06% 313
2024
Q4
$157M Buy
203,900
+72,200
+55% +$59.8M 0.02% 589
2024
Q3
$117M Sell
131,700
-208,500
-61% -$187M 0.02% 727
2024
Q2
$308M Buy
340,200
+265,300
+354% +$212M 0.05% 373
2024
Q1
$58.3M Sell
74,900
-57,700
-44% -$41.1M 0.01% 1068
2023
Q4
$77.3M Buy
132,600
+14,800
+13% +$8.64M 0.01% 914
2023
Q3
$63.3M Sell
117,800
-41,800
-26% -$21.5M 0.01% 973
2023
Q2
$74.8M Buy
159,600
+77,500
+94% +$32.5M 0.02% 851
2023
Q1
$28.2M Sell
82,100
-147,400
-64% -$49.7M 0.01% 1501
2022
Q4
$84M Buy
229,500
+138,900
+153% +$49.2M 0.02% 822
2022
Q3
$29.3M Sell
90,600
-26,000
-22% -$8.24M 0.01% 1533
2022
Q2
$37.8M Sell
116,600
-22,300
-16% -$6.69M 0.01% 1339
2022
Q1
$39.8M Buy
138,900
+39,500
+40% +$10.2M 0.01% 1470
2021
Q4
$27.5M Buy
99,400
+49,900
+101% +$12.6M 0.01% 1843
2021
Q3
$11.4M Buy
49,500
+12,300
+33% +$3.04M ﹤0.01% 2599
2021
Q2
$8.54M Sell
37,200
-90,800
-71% -$18.2M ﹤0.01% 2843
2021
Q1
$23.9M Sell
128,000
-130,000
-50% -$25.4M 0.01% 1798
2020
Q4
$43.6M Buy
258,000
+210,500
+443% +$31.4M 0.01% 1227
2020
Q3
$7.03M Sell
47,500
-69,400
-59% -$10.7M ﹤0.01% 2629
2020
Q2
$19.2M Sell
116,900
-70,400
-38% -$10.8M 0.01% 1721
2020
Q1
$26M Buy
187,300
+144,200
+335% +$19.8M 0.01% 1328
2019
Q4
$5.67M Sell
43,100
-36,800
-46% -$4.27M ﹤0.01% 2864
2019
Q3
$8.94M Buy
79,900
+59,600
+294% +$6.64M ﹤0.01% 2403
2019
Q2
$2.25M Sell
20,300
-131,800
-87% -$15.5M ﹤0.01% 3460
2019
Q1
$19.7M Sell
152,100
-355,700
-70% -$43.3M 0.01% 1881
2018
Q4
$58.8M Buy
507,800
+268,400
+112% +$30M 0.02% 971
2018
Q3
$25.7M Buy
239,400
+64,500
+37% +$6.45M 0.01% 1735
2018
Q2
$14.9M Sell
174,900
-211,900
-55% -$17.4M ﹤0.01% 2109
2018
Q1
$29.9M Buy
386,800
+93,400
+32% +$7.52M 0.01% 1528
2017
Q4
$24.8M Buy
293,400
+75,000
+34% +$6.38M 0.01% 1773
2017
Q3
$18.7M Buy
218,400
+106,900
+96% +$8.77M ﹤0.01% 2044
2017
Q2
$9.18M Sell
111,500
-28,700
-20% -$2.34M ﹤0.01% 2571
2017
Q1
$11.8M Sell
140,200
-2,625,000
-95% -$210M ﹤0.01% 2280
2016
Q4
$203M Buy
2,765,200
+1,615,800
+141% +$120M 0.06% 384
2016
Q3
$92.3M Buy
1,149,400
+304,000
+36% +$24.3M 0.03% 764
2016
Q2
$66.6M Sell
845,400
-552,600
-40% -$41.6M 0.02% 910
2016
Q1
$101M Sell
1,398,000
-99,300
-7% -$7.51M 0.03% 653
2015
Q4
$126M Sell
1,497,300
-425,600
-22% -$35.3M 0.04% 541
2015
Q3
$161M Buy
1,922,900
+706,900
+58% +$59.7M 0.05% 395
2015
Q2
$102M Buy
1,216,000
+938,300
+338% +$71.5M 0.03% 654
2015
Q1
$20.2M Buy
277,700
+10,200
+4% +$726K 0.01% 1746
2014
Q4
$18.5M Sell
267,500
-36,000
-12% -$2.43M 0.01% 1877
2014
Q3
$19.7M Sell
303,500
-245,500
-45% -$15.5M 0.01% 1796
2014
Q2
$34.1M Sell
549,000
-146,100
-21% -$8.72M 0.01% 1385
2014
Q1
$40.9M Sell
695,100
-585,500
-46% -$32.7M 0.01% 1205
2013
Q4
$65.3M Buy
1,280,600
+512,500
+67% +$25.7M 0.02% 883
2013
Q3
$38.7M Sell
768,100
-678,700
-47% -$35.5M 0.01% 1141
2013
Q2
$71.1M Buy
+1,446,800
New +$78.7M 0.03% 698

Other funds holding LLY

Goldman Sachs's LLY Position: Q1 2026 in Review

Goldman Sachs increased its Eli Lilly (LLY) stake by 6.6% in Q1 2026, buying an estimated $396M and bringing the position to 6,340,865 shares worth $5.83B. The position accounts for 0.67% of the portfolio, ranked #15.

Goldman Sachs first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.39B in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Goldman Sachs held 6,340,865 shares of Eli Lilly worth $5.83B as of Q1 2026.
  • Goldman Sachs bought 390,971 Eli Lilly shares in Q1 2026, an estimated $396M.
  • Eli Lilly made up 0.67% of Goldman Sachs's portfolio in Q1 2026, its #15 holding.
  • Goldman Sachs first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Eli Lilly position peaked at $6.39B in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.